Abstract
To evaluate the efficacy and safety of natalizumab in patients with active relapsing–remitting multiple sclerosis (MS). We included 285 MS patients receiving natalizumab. Clinical, neuroradiological and safety data were registered every 6 months. Neutralizing antibodies (NABs) were tested after 6 months of treatment. After 1 year, the annualized relapse rate decreased to 0.26, with a significant reduction compared to the previous year (2.13). At 24 months the proportion of “relapse free” patients was 78% while that of “MRI free” patients was 69%. Considering clinical and MRI cumulative activity, “disease free” patients were 63% at 24 months. A total of 18 patients showed NABs positivity. We reported 34 cases of treatment interruptions. In conclusion, our data confirm the remarkable efficacy of natalizumab in a group of patients with higher disease activity than that of pivotal studies.
Similar content being viewed by others
References
Yednock TA, Cannon C, Fritz LC et al (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4beta1 integrin. Nature 356:63–66
Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910
Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9):911–923
Conflict of interest statement
Within the past year Prof. Comi received personal compensation from Bayer-Schering, Serono Symposia International Foundation, Merck Serono International and TEVA Pharmaceutical Ind. Ltd., Sanofi-Aventis and Biogen-Dompè for consulting services. He has received personal compensation for speaking activities. TEVA Pharmaceutical Ind. Ltd, Sanofi-Aventis, Serono Symposia International Foundation, Biogen-Dompè and Bayer-Schering. Dr. LME Grimaldi has received appearance fees, travel support, research grant, from Biogen-Dompè. In the last five years Dr. A. Ghezzi received consulting and lecture fees form Bayer-Schering, Sanofi-Aventis, Novartis, Biogen-Dompè, Merk-Serono, Actelion. In the last year Dr. L. Moiola and Dr. S. Bucello received personal compensation for speaking activity from Biogen-Dompè. Dr. F. Sangalli, Dr. P. Annovazzi, Dr. A. Rizzo, Dr. M. Radaelli and Dr. G. Vitello have nothing to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sangalli, F., Moiola, L., Bucello, S. et al. Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 31 (Suppl 3), 299–302 (2011). https://doi.org/10.1007/s10072-010-0344-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-010-0344-z